Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $94.84 USD
Change Today -5.37 / -5.36%
Volume 234.5K
CBPO On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 08/31/15 All times are local (Market data is delayed by at least 15 minutes).

china biologic products inc (CBPO) Snapshot

Open
$98.77
Previous Close
$100.21
Day High
$100.25
Day Low
$93.68
52 Week High
08/6/15 - $128.00
52 Week Low
10/15/14 - $47.23
Market Cap
2.4B
Average Volume 10 Days
410.2K
EPS TTM
$3.11
Shares Outstanding
25.7M
EX-Date
--
P/E TM
30.5x
Dividend
--
Dividend Yield
--
Current Stock Chart for CHINA BIOLOGIC PRODUCTS INC (CBPO)

Related News

No related news articles were found.

china biologic products inc (CBPO) Related Businessweek News

No Related Businessweek News Found

china biologic products inc (CBPO) Details

China Biologic Products, Inc. engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia. The company also offers human hepatitis B immunoglobulin for the prevention of measles and contagious hepatitis; human immunoglobulin and immunoglobulin for intravenous injection products for original and secondary immunoglobulin deficiency, and auto-immune deficiency diseases; and Thymopolypeptides injection for the treatment of original and secondary T-cell deficiency syndromes, auto-immune deficiency diseases, and cell immunity deficiency diseases, as well as assists in the treatment for tumors. In addition, it provides human rabies immunoglobulin primarily for passive immunity from bites or claws by rabies or other infected animals; human tetanus immunoglobulin for the prevention and therapy of tetanus; placenta polypeptide for the treatment of cell immunity deficiency diseases, viral infection, and leucopenia, as well as assists in postoperative healing; human coagulation factor VIII for treating coagulopathie; and human prothrombin complex concentrate for treating congenital and acquired clotting factor II, VII, IX, X deficiency, as well as excessive anticoagulant, vitamin K deficiency, etc. Further, the company is developing human hepatitis B immunoglobulin (PH4) for intravenous injection; human fibrinogen; immune globulin intravenous; human antithrombin III; and human cytomegalovirus immunoglobulin. It distributes its products directly or through distributors. The company is headquartered in Beijing, the People's Republic of China.

1,621 Employees
Last Reported Date: 03/4/15

china biologic products inc (CBPO) Top Compensated Officers

Executive Chairman, Chief Executive Officer a...
Total Annual Compensation: $885.4K
Chief Financial Officer
Total Annual Compensation: $366.5K
Senior Corporate Vice President and Corporate...
Total Annual Compensation: $256.8K
Corporate Vice President and General Manager ...
Total Annual Compensation: $324.5K
Corporate Vice President
Total Annual Compensation: $183.6K
Compensation as of Fiscal Year 2014.

china biologic products inc (CBPO) Key Developments

China Biologic Products, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Reiterates Revenue Guidance for the Third Quarter and Fourth Quarter of 2015

China Biologic Products, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported sales of $79,068,452 compared to $60,073,984 a year ago. Income from operations was $40,240,791 compared to $28,873,235 a year ago. Earnings before income tax expense were $40,365,833 compared to $31,257,818 a year ago. Net income attributable to the company was $26,723,959 or $0.99 diluted per share compared to $19,724,955 or $0.79 diluted per share a year ago. Adjusted net income attributable to the company - non GAAP was $28,582,627 or $1.06 diluted per share compared to $20,522,830 or $0.82 diluted per share a year ago. Total sales increase was primarily attributable to increases in sales volume of major plasma-based products. For the six months, the company reported sales of $149,422,783 compared to $116,340,561 a year ago. Income from operations was $74,987,342 compared to $56,851,968 a year ago. Earnings before income tax expense were $75,637,343 compared to $60,548,585 a year ago. Net income attributable to the company was $49,886,431 or $1.86 diluted per share compared to $37,998,626 or $1.47 diluted per share a year ago. Adjusted net income attributable to the company - non GAAP was $53,533,033 or $1.99 diluted per share compared to $39,594,376 or $1.53 diluted per share a year ago. Net cash provided by operating activities was $34,561,277 compared to $39,027,261 a year ago. Payment for property, plant and equipment was $16,486,212 compared with $10,243,198 for the same period last year. Payment for intangible assets and land use right was $4,205,678 compared with $1,227,914 for the same period last year. Decrease in net cash provided by operating activities was primarily due to the increases in accounts receivable and inventories during the six months ended June 30, 2015 as compared to the same period in 2014, partially offset by increases in net income and accounts payable during the same comparable periods. The company expect year-over-year third quarter sales growth rate to be lower than the first two quarters of 2015, primarily due to a relatively high volume sold in the third quarter of 2014 after receiving the first batch approval in July 2014 at the upgraded Guizhou facility. The company expect its year-over-year fourth quarter sales growth rate to increase over the third quarter as it benefit from the sales of products made from its purchased plasma.

China Biologic Products, Inc. to Report Q2, 2015 Results on Aug 05, 2015

China Biologic Products, Inc. announced that they will report Q2, 2015 results at 5:00 PM, China Standard Time on Aug 05, 2015

China Biologic Products, Inc., Q2 2015 Earnings Call, Aug 06, 2015

China Biologic Products, Inc., Q2 2015 Earnings Call, Aug 06, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CBPO:US $94.84 USD -5.37

CBPO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Hualan Biological Engineering Inc CNY37.62 CNY -1.55
Northwest Biotherapeutics Inc $7.70 USD -0.41
Opexa Therapeutics Inc $0.42 USD +0.0354
Shanghai RAAS Blood Products Co Ltd CNY75.35 CNY -1.27
StemCells Inc $0.41 USD +0.01
View Industry Companies
 

Industry Analysis

CBPO

Industry Average

Valuation CBPO Industry Range
Price/Earnings 32.3x
Price/Sales 9.1x
Price/Book 7.4x
Price/Cash Flow 31.1x
TEV/Sales 8.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CHINA BIOLOGIC PRODUCTS INC, please visit www.chinabiologic.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.